At the last Annual Representative Meeting of the British Medical Association a motion was passed that `certain additional cannabinoids should be legalized for wider medicinal use.'' This report supports this landmark statement by reviewing the scientific evidence for the therapeutic use of cannabinoids and sets the agenda for change. It will be wel
At the last Annual Representative Meeting of the British Medical Association a motion was passed that `certain additional cannabinoids should be legalized for wider medicinal use.'' This report supports this landmark statement by reviewing the scientific evidence for the therapeutic use of cannabinoids and sets the agenda for change. It will be welHinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1. The Legal Situation 2. International Developments 3. PHARMACOLOGY 4. Constituents of Cannabis; Natural and Synthetic Cannabinoids 5. Pharmacokinetics 6. Pharmacodynamics 7. Actions of Cannabis in Man 8. THERAPEUTIC USES 9. Nausea and Vomiting Associated with Cancer Chemotherapy 10. Muscle Spasticity 11. Pain 12. Anorexia 13. Epilepsy 14. Glaucoma 15. Bronchial Asthma 16. Mood Disorders, Psychiatric Conditions 17. ADVERSE EFFECTS OF CANNABIS IN CLINICAL USE 18. Acute Effects Commonly Observed in Clinical Settings 19. Other Acute Effects Relevant to Therapeutic Use 20. Effects of Chronic Dosage Relevant to Therapeutic Use 21. Precautions for Prescribed Cannabinoids 22. DOSAGE AND ROUTES OF ADMINISTRATION 23. FUTURE PROSPECTS 24. SUMMARY AND RECOMMENDATIONS
1. The Legal Situation 2. International Developments 3. PHARMACOLOGY 4. Constituents of Cannabis; Natural and Synthetic Cannabinoids 5. Pharmacokinetics 6. Pharmacodynamics 7. Actions of Cannabis in Man 8. THERAPEUTIC USES 9. Nausea and Vomiting Associated with Cancer Chemotherapy 10. Muscle Spasticity 11. Pain 12. Anorexia 13. Epilepsy 14. Glaucoma 15. Bronchial Asthma 16. Mood Disorders, Psychiatric Conditions 17. ADVERSE EFFECTS OF CANNABIS IN CLINICAL USE 18. Acute Effects Commonly Observed in Clinical Settings 19. Other Acute Effects Relevant to Therapeutic Use 20. Effects of Chronic Dosage Relevant to Therapeutic Use 21. Precautions for Prescribed Cannabinoids 22. DOSAGE AND ROUTES OF ADMINISTRATION 23. FUTURE PROSPECTS 24. SUMMARY AND RECOMMENDATIONS
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826